Phase 1 Trial Featuring First shRNA-Edited CAR-T Therapy to Begin
FDA approves allogenic CAR T cells targeted at BCMA for phase 1 trial in relapsed/refractory multiple myeloma.
CAR-T Therapy
Can Culturing CAR T Cells With Ibrutinib Improve Their Efficacy in CLL?
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Development of a Tool to Predict Neurotoxicity Associated With CAR-T Therapy
The occurrence, severity, and need for treatment of cytokine release syndrome were key parameters in the assessment of CAR-T–related neurotoxicity risk.
New NCCN Patient Guidelines Feature Immunotherapy, CAR-T Side Effects
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
The data reinforce the need for direct comparison of CAR-T and autologous transplantation.
Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR-T Deemed Effective in Heavily Pretreated, Refractory Multiple Myeloma
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient.
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
